Novo Nordisk A/S (NVO) — Quantitative Forecast & Factor Scores
NVO screens as high-quality and attractively valued — DCF model implies a +98% margin of safety at current levels.
NVO's quantitative grade is Strong Buy, with significant tail risk (CVaR -45.5%), and quality metrics (net margin 33%, ROE 61%). Novo Nordisk A/S (NVO) trades at $36.04 with a valuation grade of Strong Buy: a trailing P/E of 10.1x at a 54% discount to sector median, net margins of 33.1%, a DCF-implied intrinsic range of $51–$92 suggesting a +98% margin of safety, beta 0.27 (defensive risk profile).
Key Takeaways
- Valuation: Strong Buy grade — P/E 10.1x — DCF range $51–$92 implies +98% margin of safety
- Risk: CVaR -45.5% (95th percentile, 1-month) indicates moderate tail exposure; beta of 0.27 amplifies broad market moves in both directions
- Strengths: Quality 5.0/5, Size 4.0/5, 33% net margin, 61% ROE dominate the factor profile
- Watch: Monitor earnings delivery — premium multiples leave limited margin for misses
Quantitative Factor Profile
Key Metrics
| Metric | Value |
|---|---|
| Current Price | $36.04 |
| P/E Ratio (TTM) | 10.1x |
| Forward P/E | 10.6x |
| P/S Ratio | 0.5 |
| EV/EBITDA | 1.7 |
| Beta | 0.27 |
| Net Margin | 33.1% |
| ROE | 60.7% |
| Debt/Equity | 67.5% |
| Dividend Yield | 5.16% |
| CVaR (95%, 1M) | -45.5% |
| Market Cap | $161.2B |
Earnings History
| Quarter | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| Q4 2025 | $5.90 | $6.04 | +2.3% ✓ |
| Q3 2025 | $4.24 | $4.50 | +6.0% ✓ |
| Q2 2025 | $6.00 | $5.96 | -0.7% ✗ |
| Q1 2025 | $6.07 | $6.53 | +7.5% ✓ |
NVO vs. Sector Peers
| Ticker | P/E (TTM) | Beta | CVaR-95 | Net Margin |
|---|---|---|---|---|
| NVO | 10.1x | 0.27 | -45.5% | 33.1% |
| LLY | 38.3x | 0.43 | -19.8% | 31.7% |
| PFE | 19.9x | 0.41 | -7.5% | 12.4% |
| JNJ | 21.8x | 0.33 | -3.8% | 28.5% |
| ABBV | 88.4x | 0.33 | -8.9% | 6.9% |
NVO screens as an exceptional-quality business, at an attractive entry point relative to intrinsic value. Three of the last four quarters beat consensus — execution is solid.
NVO trades at 10.1x trailing earnings — 54% below the Healthcare sector median of 22.0x. The DCF model implies a +98% margin of safety — the risk/reward is currently skewed to the upside.
The model points to a strong buy and the DCF math backs it — there is real margin of safety here, which is rare at this stage of the cycle. The DCF gap is striking — the model sees 98% upside, and market consensus is not pricing it. I watch for the catalyst that closes that gap: an earnings beat that resets forward estimates, a sector re-rating, or a margin inflection. Without a visible catalyst, valuation gaps can stay wide longer than logic suggests they should. If the thesis holds across the next two quarters, I would be comfortable carrying this at a meaningful weight. If not — specifically, if margins disappoint or the earnings beat streak breaks — I would reduce before the market fully reprices.
Is NVO a buy, hold, or sell?
NVO carries a valuation grade of Strong Buy. At a trailing P/E of 10.1, the stock trades at a 54% discount to the Healthcare sector median of 22.0x. Our discounted cash flow model produces an intrinsic range of $51–$92 — implying a +98% margin of safety at the current price of $36.04. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate.
The company has beaten estimates in 75% of recent quarters. The most recent quarter delivered a 2.3% earnings surprise. Analyst estimate revisions are trending flat.
What are NVO's key risk factors?
With a beta of 0.27, NVO exhibits a low-volatility risk profile relative to the broad market. The 95th-percentile CVaR of -45.5% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 4.5% of total portfolio loss in the worst 5% of months. Net margins of 33.1% are significantly above the Healthcare sector average of 18%, reflecting durable pricing power. Return on equity of 60.7% indicates highly efficient capital allocation. The balance sheet is conservatively leveraged at 67% debt-to-equity.
The options market shows a put/call ratio of 1.28, reflecting a notably bearish skew in derivative positioning. Implied volatility of 50.2% exceeds realized volatility of 30.6% by 20 points, suggesting options are pricing in elevated risk. Short interest is low at 0.8% of float, suggesting limited bearish conviction.
How does NVO fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — NVO carries a beta of 0.27, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
As a Healthcare constituent, NVO's risk profile should be evaluated alongside sector peers when constructing diversified portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The NVO analysis here is a single node in that larger structure.
Run NVO in Asset Lens
Live DCF valuation, Monte Carlo simulation, options flow intelligence, and full factor decomposition — updated in real time. Free, no account required.
Launch Live Analysis →This analysis is produced using a systematic quantitative framework applied to market data and does not constitute investment advice. Prose commentary is AI-assisted and generated from structured quantitative inputs. All data and metrics are as of 2026-03-28 and are point-in-time estimates subject to revision without notice. CVaR figures are based on historical simulation and do not guarantee future outcomes. DCF ranges and upgrade/downgrade triggers are forward-looking statements based on current assumptions and may not materialise. Past performance does not guarantee future results. This analysis does not account for individual circumstances, tax position, or investment objectives — consult a qualified financial advisor before making investment decisions. This content is intended for informational purposes only and does not constitute regulated investment advice under MiFID II or FCA guidelines. This content is not intended for US persons or residents of jurisdictions where its distribution would be contrary to local law or regulation. This service is not directed at residents of Finland, Sweden, Norway, Denmark, Iceland, or Poland. The author may hold long or short positions in securities mentioned in this analysis. Nothing on this page represents a solicitation to buy or sell any security. A.L. Capital Advisory is an independent private advisory practice and is not affiliated with Novo Nordisk A/S.